Further coverage of the acquisition highlights how Kelonia’s in vivo gene placement system (iGPS) adds another clinical-stage asset to Lilly’s genetic medicines roadmap. The buyer’s broader objective is to build a scalable “onetime infusion” CAR-T engine that can be delivered in routine clinical settings. Kelonia’s lead program, KLN-1010, is in Phase I development for relapsed/refractory multiple myeloma (NCT07075185). The companies framed early data around minimal residual disease (MRD) negativity in the earliest cohort and pointed to an FDA-cleared IND that enables multi-site expansion in the U.S. Investor commentary in the reporting also tied the transaction to a high-profile return for early backers, reinforcing how in vivo CAR-T has attracted capital as a potential operational advantage over conventional ex vivo workflows.